Sun Pharmaceutical Industries Ltd

Q4 Results Highlights: Around 164 companies are announcing their results for the January-March quarter of the financial year 2025.

Sun Pharma Q3 net profit rises 15% to Rs 2,903.4 crore, meets estimate; Rs 10.5 dividend declared

Sun Pharma Q3 FY25 results: The drugmaker posted steady growth in Q3 FY25, with profit rising on strong domestic and emerging market sales, while US business remained weak.

Sun Pharma’s Q2 net profit jumps 28% on-year to Rs 3,040 crore, beats expectations

Sun Pharmaceutical Q2 FY25 Results: Analysts expected India's largest drugmaker's net profit to jump, led by favourable seasonality and strong specialty sales.

Sun Pharma Q4 results: Net profit rises 34% to Rs 2,654.5 crore, final dividend of Rs 5 announced

Sun Pharma Q4: Consolidated revenue came in at Rs 11,982.9 crore, up 9 percent from the year-ago period

Small pharma cos curtailing investments in the US, says Jefferies

Failure to capture market share, supply disruptions from non-compliance of current good manufacturing practices imposed by the US Food and Drugs Administration are some of the reasons triggering the move.

Sun Pharma Q3 net profit rises 5% to Rs 2,166 crore

The company also reported a 14 percent increase in consolidated revenue at Rs 11,241 crore as against Rs 9,863 crore in the year-ago period.

Sun Pharma profit may decline 10% in Q3 on poor operating performance

Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth.

India Inc throws up a mixed bag in Q2 amid global headwinds, local play stays strong

Excluding global cyclicals, profits of the Nifty50 companies would have grown 25 percent on-year, while, excluding BFSI companies, profits would have decreased 14 percent, say analysts

Sun Pharma’s specialty drugs bet is beginning to pay off

Sun Pharmaceutical’s foray into specialty drugs was in some ways driven by an existential threat posed by rising competition to its generic drug business in the US. In the September quarter, it reported sales of $200 million from specialty drugs in the US, up 27.5 percent YoY

Sun Pharma consolidated net profit rises more than 8%, beats estimate

The drugmaker reported 13.8 percent growth in consolidated revenue from operations

Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs

Sun Pharmaceutical’s consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio

Sun Pharma Q1 Result | Consolidated profit rises 43% YoY to Rs 2,061 crore

Sun Pharma Q1 Result: The company's revenue was up 11% at Rs 10,762 crore from Rs 9,719 crore in the year-ago quarter

Sun Pharma Q1 Results Preview | Profit may rise 16%; revenue likely to dip 13%

The YoY growth is likely to be driven by growth in US business, strong performance from specialty product portfolio, and modest growth in domestic formulations. Margins however, are likely to take a dent due to inflationary pressures

Pharma Q4 Preview | Despite strong domestic demand and modest US growth, cost pressure, lower prices to dent margins

Raw material prices aggravated due to COVID-led lockdowns in China and spike in logistics costs to overshadow revenue growth

Pharma Q3 Preview | Lukewarm growth expected as US market sales slowdown

The sector will also be affected by a high base of the year-ago quarter with its impact being felt acutely on the operating performance of drugmakers as analysts expect EBITDA to grow by just 5 percent in the December quarter.

Sun Pharma: Q2 Results Preview – Revenues to increase by ~10% and Adjusted PAT by ~8%% on a YOY basis

Experts expect the revenues to grow ~10% on a YOY basis due to growth in both Domestic formulations and US specialty sales.

Sun Pharma's senior exec, wife settle insider trading case with Sebi

At the time of alleged violation, Abhay Arvind Gandhi was the CEO of Sun Pharma Laboratories Ltd (SPLL), a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd.

Sun Pharma to make unit distributor for local formulations biz

The company had last week asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower relating to certain transactions involving the company and its co-promoter that led to a sell-off in the company's shares.

Sun to sell Ranbaxy's 2 divisions to Strides for Rs 165 cr

Sun Pharma and Strides have entered into a definitive agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India, the company said in a statement.

Daiichi Sankyo to offload stake in Sun Pharma

As part of the deal, Ranbaxy shareholders were to receive 0.8 Sun Pharma shares for every Ranbaxy share they held. Daiichi Sankyo, which had acquired a majority stake in Ranbaxy in 2008 for around Rs 22,000 crore, held 63.4 percent in the Gurgaon-based firm at the time of the merger.

FDA aapproves generic version of cancer drug Doxil

US health regulators have approved a generic version of the cancer drug Doxil in a move that could ease a months-long shortage that has threatened the lives of thousands of patients.

Technical outlook for the fortnight: Nirmal Bang

The Indian markets were battered heavily in the month of August. And while the bloodbath on the bourses led to the markets taking a beating by almost 8.5%, the Sensex dipped to alarming levels, hinting at a repeat of the economic gloom of 2008.

Sun Pharma to sell some Merck diabetes drugs in India

Sun Pharmaceutical Industries Ltd has entered into a deal to market Merck's diabetes drugs - sitagliptin and sitagliptin plus metformin in India, the two drugmakers said in a statement on Monday.

Merck, Sun Pharma eyeing India marketing tie-up?

US drugmaker Merck & Co is close to striking a marketing alliance with Sun Pharmaceutical Industries Ltd for the Indian market, the Mint reported on Monday.